BioPharma SHAKTI and three chemical parks get budget push

A ₹13,000-crore budget bet to make India a biologics hub and lift its share of the world chemical market.

What happened

• The Ministry of Chemicals and Fertilizers framed the Union Budget's ₹13,000-crore allocation for BioPharma SHAKTI and three Dedicated Chemical Parks as a long-horizon industrial bet, in remarks by Union Minister Shri J. P. Nadda at a post-budget webinar.
• Of the total, ₹10,000 crore over five years goes to the BioPharma mission aimed at biologics and next-generation therapies; ₹3,300 crore funds the three world-class chemical parks.
• The parks are designed as plug-and-play estates with advanced effluent treatment, integrated logistics and built-in safety, expected to cut operating costs 20–40% through industrial symbiosis.
• The minister tied the move to a structural shift in global medicine: roughly 40% of medicines worldwide are projected to be biologics by 2035, with about $300 billion of patents expiring by 2030.
• Capturing even a 1% share of the global biosimilars market could be worth around ₹2 lakh crore a year to India, the ministry said.
• Enabling reforms named alongside the money: a strengthened drug regulator (CDSCO), 1,000 clinical-trial sites, and reform of the NIPER pharmaceutical-education network.

Background & context

This is a Budget-anchored industrial-policy announcement rather than a stand-alone new law, and it sits inside the Department of Pharmaceuticals and the Department of Chemicals & Petrochemicals, both housed under the Ministry of Chemicals and Fertilizers. The same budget cycle bundled it with a wider package the Prime Minister flagged at the post-budget webinar — alongside a Carbon Capture, Utilisation and Storage (CCUS) Mission and Dedicated Rare Earth Corridors — under the framing "build more, produce more, connect more, export more." For exam purposes the durable, nameable entities here are two: the BioPharma SHAKTI Mission and the Dedicated Chemical Parks, supported by two institutions an aspirant must already know — CDSCO and NIPER.

The lineage matters. India is already described as the "pharmacy of the world," but that reputation rests almost entirely on generics — small-molecule, chemically synthesised copies of off-patent drugs, where India is among the largest suppliers by volume. BioPharma SHAKTI is a deliberate attempt to move up the value chain from generics to biologics and biosimilars. A biologic is a large, complex medicine produced inside living cells through fermentation or cell culture — monoclonal antibodies, vaccines, insulin, gene and cell therapies — rather than mixed in a chemical reactor. A biosimilar is the biologic analogue of a generic: a highly similar, approved version of an original biologic after its patent lapses. Because biologics are grown, not synthesised, they cannot be copied atom-for-atom, so "biosimilar" (not "generic") is the correct term, and regulatory approval is harder — which is exactly why the announcement pairs the money with a stronger regulator and more trial capacity.

The chemical-parks half of the package addresses a different bottleneck: India's specialty- and bulk-chemicals industry has long lacked integrated, environmentally compliant land with ready utilities, pushing investment to competitors. The parks are conceived on a circular-economy logic — clustering plants so one unit's waste stream or by-product or shared utility becomes another's input ("industrial symbiosis"), which is where the projected 20–40% cost reduction comes from. Together the two halves are meant to reduce import dependence in both advanced medicines and chemical intermediates, including the active pharmaceutical ingredients (APIs) and key starting materials India still buys heavily from abroad.

For Prelims

• BioPharma SHAKTI Mission: Budget-announced mission, ₹10,000 crore over five years, under the Ministry of Chemicals and Fertilizers; goal is to make India a global hub in biologics and next-generation therapies (not generics).
• Three Dedicated Chemical Parks: ₹3,300 crore for three world-class parks — plug-and-play utilities, advanced effluent treatment, integrated logistics, built-in safety; 20–40% cost cut via industrial symbiosis (circular economy).
• Total package: ₹13,000 crore (₹10,000 cr + ₹3,300 cr), described as a "strategic bet on India's future."
• Biologics opportunity: ~40% of global medicines to be biologics by 2035; ~$300 billion of patents expire by 2030; a 1% global biosimilars share ≈ ₹2 lakh crore/yr for India.
• Chemical-sector numbers: India's chemical output is ₹19.4 lakh crore, a 3% global share now, targeted to rise to 5–6% by 2030 and a $1 trillion turnover by 2040.
• CDSCO (Central Drugs Standard Control Organisation): India's central drug regulator, under the Directorate General of Health Services, Ministry of Health & Family Welfare; headed by the Drugs Controller General of India (DCGI); to be strengthened for faster approval of biosimilars and fermentation-based drugs.
• NIPER (National Institute of Pharmaceutical Education and Research): the institute(s) of national importance for pharma education and research, under the Department of Pharmaceuticals; to be reformed; the first and flagship campus is at Mohali.
• Clinical-trial capacity: plan for 1,000 clinical-trial sites to support the biologics push.
• Generics anchor: India is already the "pharmacy of the world" via generics; SHAKTI is the move beyond generics into biologics.

The full comparative set (the family it belongs to). SHAKTI is one of several recent sector-building interventions for Indian pharma and chemicals — useful for "how many of these / match the pairs" questions: the Production Linked Incentive (PLI) scheme for pharmaceuticals and the separate PLI for bulk drugs/KSMs-APIs; the Bulk Drug Parks scheme (three bulk-drug parks sanctioned to cut API import dependence); the Promotion of Medical Device Parks scheme; the Strengthening of Pharmaceutical Industry (SPI) scheme; and the National Policy on Research and Development and Innovation in the Pharma-MedTech Sector with its PRIP scheme. BioPharma SHAKTI is distinct from all of these in that it targets biologics/biosimilars specifically, while the older schemes mostly targeted generics, APIs/bulk drugs, and devices.

For UPSC: BioPharma SHAKTI = ₹10,000 cr over 5 years for biologics (not generics); a separate ₹3,300 cr funds 3 Dedicated Chemical Parks; CDSCO is India's central drug regulator that will clear biosimilars, and NIPER is the pharma-education institute being reformed.

What it is NOT: SHAKTI is not a generics scheme and not the PLI scheme — it specifically targets biologics and biosimilars. The ₹3,300-cr Chemical Parks are not the older Bulk Drug Parks (which sit on the pharma/API side); they are general-chemical industrial estates. CDSCO is not under the Ministry of Chemicals and Fertilizers — it is under the Ministry of Health & Family Welfare — even though this announcement comes from Chemicals & Fertilizers. And a "biosimilar" is not a "generic": generics copy small chemical molecules; biosimilars are highly-similar versions of complex biologics.

Why it matters

The announcement answers a specific strategic vulnerability. India's pharma strength is volume-led and low-margin, concentrated in generics, while the high-value future of medicine — monoclonal antibodies, cell and gene therapies, GLP-class metabolic drugs — is biologic and capital-intensive. The patent cliff is the opening: as roughly $300 billion of originator biologics lose protection by 2030, the country that can manufacture approved biosimilars at scale captures a market that did not previously exist for copy-makers. Costing it at ₹2 lakh crore a year for just a 1% slice reframes biologics from a research aspiration into an export-and-jobs argument, which is why it lands in a budget speech rather than a science ministry.

The chemical-parks leg addresses the supply side of the same competitiveness problem. India runs a persistent trade deficit in chemicals and imports a large share of its APIs and key starting materials, much of it from a single source country — an exposure the pandemic made visible. Plug-and-play parks with shared effluent treatment lower both the cost and the environmental-clearance friction that have historically pushed chemical investment elsewhere, and the circular-economy clustering is the mechanism for the 20–40% saving. Reading the two halves together, the policy is an import-substitution and value-chain-deepening play: make the inputs (chemicals, APIs) at home, and climb from generics to biologics in the output. The honest caveat the package itself implies is execution — biologics require regulatory capacity, skilled scientists and clinical infrastructure that money alone does not create, which is precisely why CDSCO strengthening, 1,000 trial sites and NIPER reform are bundled in rather than left as afterthoughts.

For Mains

Related: BioPharma SHAKTI Mission · Economy & Finance · this week's cards